BIAL
↗São Mamede do Coronado, Trofa, Porto, Portugal
BIAL is a Portuguese pharmaceutical company founded in 1924, specializing in innovative therapeutic solutions in central nervous system (CNS), cardiology, and allergen immunotherapy. The company is dedicated to discovering, developing, and commercializing pharmaceutical products for rare diseases and neuroscience indications. With a history spanning 100 years (celebrated centenary in 2024), BIAL has evolved from a regional player to an international pharmaceutical company with presence in 58+ countries across 4 continents. The company invests over 20% of annual turnover into R&D, focusing on disease-modifying therapies and first-in-class treatments for underserved patient populations.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharmaceuticals / Neuroscience
SIZE & FINANCIALS
Employees:501-1000
Revenue:$300M-$350M
Founded:1924
Ownership:private
Status:operating
FUNDING
Stage:Private
PIPELINE
Stage:Phase 2 (lead candidate)
Lead Drug Stage:BIA 28-6156 - Phase 2 for GBA-Associated Parkinson's Disease
Modalities:Small molecule, Oral therapeutics
Active Trials:2
Trial Phases:Phase 2: 1
FDA Approvals:2
EMA Approvals:2
CORPORATE STRUCTURE
Subsidiaries:BIAL Biotech (USA), BIAL Spain, BIAL Germany, BIAL United Kingdom, BIAL Italy, BIAL Switzerland
Key Partnerships:Lysosomal Therapeutics acquisition (2020s) - provided BIA 28-6156 program and R&D team for US BIAL Biotech subsidiary
COMPETITION
Position:Niche Player / Emerging
Competitors:Biogen (Denali collaboration - DNL151/BIIB122 for LRRK2-PD, Phase 2b), Eli Lilly (GBA-PD via Prevail acquisition - PROPEL Phase I/II trial), AbbVie, Boehringer Ingelheim, Amgen, Teva Pharmaceutical Industries, Novartis, Roche +2 more
LEADERSHIP
Key Executives:
António Portela - Chief Executive Officer (CEO)
Miguel Portela - Chief Corporate Officer
Joerg Holenz - Chief Scientific Officer
Max Bricchi - Chief Commercial Officer
Jasmine Zhong - Chief Financial Officer (Appointed November 2025)
Scientific Founders:Álvaro Portela (founder, 1924) - great-grandfather of current CEO António Portela
Board Members:Non-Executive Members: Ricard Pilnik, Melanie Lee, Pierluigi Antonelli, José Redondo
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of BIAL and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BIAL. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.